Fig. 2: MK-8776/olaparib combination is more effective in MNA and MYCN-OE neuroblastoma models.
From: A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
A Viability assay performed on two syngeneic MYCN-OE cell models (inducible SHEP Tet21/N, MYCN± and SK-N-SH and SK-N-MYC pair) after continuous treatment with different doses of MK-8776 alone or in combination with olaparib (10 µM), for 48 h. Data are reported as mean (+SD) of three independent experiments. Cell viability was calculated as the percentage of untreated controls. MK-8776 IC50 values (µM) are reported close to each curve. B WB analysis performed on whole-cell lysates of MYCN-OE cells models for MYCN expression. β-actin was used as loading control. C Mean IC50s ( +SD) of MK-8776 dosed alone or in combination with olaparib in all non-MNA and MNA cells represented in supplementary fig. 1. IC50 mean values (µM) are reported above the bars.
